Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).
TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...
Morgans's healthcare analyst Iain Wilkie describes 2024 as "pretty patchy" for the ASX healthcare sector, which has ...
CopyBet review JAK1 inhibitor GVHD phase III clinical trial failed Gelesis Secures Over $84 Million in New Funding to Support Commercialization of PLENIT ...
fantasy cricket expert Strategies for the development of new drugs for graft-versus-host disease (GVHD) $100 million! Hausen Pharmaceuticals licenses EQRx to acquire rights to Ametinib outside China ...
INR:4950. january 2023 ka satta king Academician Chen Wei: The Chinese virus "hunter" who "strikes back" in retrograde HEC Pharmaceutical's "Recombinan ...
INR:6468. gta san 1 century-old miracle drug & 2 billion-dollar products & 4 blockbuster drugs: the future of antithrombotic drugs is still promising Strategies for the d ...
INR:8172. mobile app Roche releases new data from two-year study of risdiplam in infants, children and adults with SMA Shengde's diabetes drug candidate CS02 Phase II ...
INR:5558. rummy star 3 patti Nature review: New force in cancer immunotherapy - NK cell therapy Strategies for the development of new drugs for graft-versus-ho ...
While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...
Meiji Seika Pharma announced the establishment of a local subsidiary, "Taiwan Meiji Pharma Co., Ltd." (Headquarters: Taipei ...
New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!